The Dog Aging Project Just Published Something That Changes Longevity Science

The Dog Aging Project's rapamycin trial results are in. Here is what they show and why they change the landscape of human longevity research.

The Dog Aging Project's controlled trial of low-dose rapamycin in middle-aged dogs — completed and reported in early April 2026 — has produced the specific results that human longevity researchers have been waiting for with an intensity that reflects how much depends on the answer.

The headline findings: dogs in the rapamycin treatment group showed measurably better cardiac function after 10 weeks of treatment compared to the placebo group. The specific measure — a standard echocardiographic assessment of heart function — showed improvements in the treatment group that are statistically significant and clinically meaningful. There was no increase in adverse events in the treatment group compared to placebo at the doses used.

Why cardiac function matters for longevity: cardiac aging is one of the primary drivers of mammalian lifespan limitation. Hearts that maintain better function longer produce longer healthy lifespans. A drug that demonstrably improves cardiac function in aging dogs is a drug that may — with appropriate qualification for species-specific differences — do something similar in aging humans.

The human longevity research community's response has been enthusiastic but measured: the measures — the 'appropriately qualified' part of the previous sentence. Dogs are the closest animal model to humans in terms of environmental exposure (shared household environment) and some aspects of disease presentation. But dogs' cardiac aging mechanisms have specific differences from human cardiac aging that mean the rapamycin results cannot be directly extrapolated to human benefit without human clinical trials.

Those trials are now being planned. The Dog Aging Project results provide the specific animal model data that human trials need as foundation: safety at the dose range used, and the specific cardiac outcome measure that a human trial would target. The FDA's standard for human trial approval typically requires rodent model data plus one additional animal model — the Dog Aging Project provides that second model data for rapamycin's cardiac aging effects.